Fenimore Asset Management purchased 405,620 shares of Agilent Technologies. Despite ongoing longer-term uptrend and revenue growth, the share price of Agilent Technologies has experienced an initial pullback and is down by 12% since the last earnings report. It received upgrades from analysts and raised its 2025 revenue guidance based on its strong Q3 sales surge. Agilent Technologies' stock performance, even when compared to other healthcare stocks, is underperforming the healthcare sector. Analysts are, however, moderate buyers. The company's balance sheet is in good health, with new CFO Adam Elinoff joining to drive strategic transformation. Its GMP-Ready xCELLigence software could potentially reshape investors' outlook. Agilent Technologies is in partnership with AI firm Lunit, advancing cancer diagnostics. It presented at the 44th Annual J.P. Morgan Healthcare Conference and has expectations for a 6-8% revenue growth in Q1. Despite the market's disapproval of Agilent's new earnings forecast, they are reportedly bullish due to recent results.
Agilent Technologies A News Analytics from Wed, 07 May 2025 07:00:00 GMT to Sat, 03 Jan 2026 18:41:49 GMT -
Rating 5
- Innovation 8
- Information 7
- Rumor -2
